A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a contract development and manufacturing organization (“CDMO”) that provides a comprehensive range of biologics manufacturing services from process development to Current Good Manufacturing Practices (“CGMP”) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. We pair CGMP biomanufacturing and quality control expertise with cutting edge capabilities in immunoassays, molecular assays, and bioanalytical methods to support the production of cell- and gene-based therapies as well as large molecule biologics. Our services include clinical and commercial drug substance manufacturing, release and stability testing and variety of process development services, including upstream and downstream development and optimization, analytical method development, as well as cell line development, testing and characterization. Our San Antonio, TX facility commenced operations in September 2022.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 1.7M | - | 7.0M | - | - | - |
| Net Income | -25M | -33M | - | -43M | -35M | -26M |
| EPS | $-4.18 | $-13.04 | $-347.50 | $-340.00 | $-282.00 | $-326.00 |
| Free Cash Flow | -15M | -27M | -34M | -26M | -40M | -22M |
| ROIC | -507.5% | -175.7% | - | -54.7% | -30.9% | -22.4% |
| Gross Margin | 24.1% | - | 60.9% | - | - | - |
| Debt/Equity | 0.00 | 1.58 | 0.34 | 0.08 | 0.01 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -34M | -34M | -42M | -40M | -35M | -26M |
| Operating Margin | -1992.9% | - | -600.9% | - | - | - |
| ROE | 0.0% | -174.1% | - | -58.8% | -31.0% | -22.4% |
| Shares Outstanding | 61M | 12M | 12M | 0M | 0M | 0M |
Scorpius Holdings, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 60.9%.
Scorpius Holdings, Inc. (SCPX) has a 5-year average return on invested capital (ROIC) of -70.9%. This is below average and may indicate limited pricing power.
Scorpius Holdings, Inc. (SCPX) has a market capitalization of $611K. It is classified as a small-cap stock.
Scorpius Holdings, Inc. (SCPX) does not currently pay a regular dividend.
Scorpius Holdings, Inc. (SCPX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Scorpius Holdings, Inc. (SCPX) generated $-27 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Scorpius Holdings, Inc. (SCPX) has a debt-to-equity ratio of 1.58. This indicates higher leverage, which may increase financial risk.
Scorpius Holdings, Inc. (SCPX) reported earnings per share (EPS) of $-13.04 in its most recent fiscal year.
Scorpius Holdings, Inc. (SCPX) has a return on equity (ROE) of -174.1%. A negative ROE may indicate losses or negative equity.
Scorpius Holdings, Inc. (SCPX) has a 5-year average gross margin of 60.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 11 years of financial data for Scorpius Holdings, Inc. (SCPX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Scorpius Holdings, Inc. (SCPX) has a book value per share of $0.51, based on its most recent annual SEC filing.